Ai Cure Technologies presents AiView digital health solution at CNS Summit

Published on November 19, 2012 at 11:41 PM · No Comments

New York City-based Ai Cure Technologies opened the Innovation Showcase at CNS Summit in Boca Raton, Fla, with a presentation of its flagship digital health solution,  AiView™. The interactive computer-vision software makes use of the webcam on a smartphone or tablet computer to automatically monitor medication adherence in clinical trials and ongoing care settings.

Clinical trial coordinators and healthcare providers can use the technology to automatically monitor patient medication adherence in real-time. Using their smartphones or tablets, patients are alerted to take their medication and can activate the system which will confirm their identity, the medication and confirm medication ingestion. The simple process takes 15 seconds to complete. Adherence data are immediately and securely transmitted to a centralized dashboard. Nonadherence events, including missed doses or incorrect medication ingestion, trigger alerts that allow coordinators or providers to intervene immediately, using a variety of integrated communication options.

"Through our patent-pending computer vision technology, we're able to simply and inexpensively automate the process of watching a patient take their medication - otherwise known as directly observed therapy (DOT) - and extend this approach to a population level. This type of monitoring ensures that the validity of clinical trial data is not compromised by medication nonadherence," said Adam Hanina, Chairman and CEO of Ai Cure Technologies, Inc. "We've found that even patients who may be considered high-risk enjoy interacting with the system."

As the system is software-based and does not require any alteration to the medication, AiView can be quickly rolled out into a clinical trial. And unlike self-reported text messaging, the system provides visual confirmation that the medication has been correctly ingested. AiView is commercially available and is currently operational in clinical trials in North America.

AiView is HIPAA and 21 CFR Part 11 compliant.

Source:

Ai Cure Technologies, Inc.

Posted in: Device / Technology News | Healthcare News

Tags: , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma